These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2872801)

  • 21. Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin.
    McNeil JJ; Drummer OH; Conway EL; Workman BS; Louis WJ
    J Cardiovasc Pharmacol; 1987 Aug; 10(2):168-75. PubMed ID: 2441167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of alpha 1-adrenoceptor blockade on the development of hypertension in the spontaneously hypertensive rat.
    Jonsson JR; Head RJ; Frewin DB
    Eur J Pharmacol; 1992 Feb; 211(2):263-8. PubMed ID: 1351850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute hemodynamic effects of terazosin in hypertensive and normotensive patients.
    Strom JA; Zola B; Frishman W; Laddu A; Wexler JP; Carlson K; Jordan A
    Am Heart J; 1991 Sep; 122(3 Pt 2):892-900. PubMed ID: 1678919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Terazosin: intravenous safety evaluation in rats.
    Fort FL; Tekeli S; Majors K; Heyman IA; Cusick PK; Kesterson JW
    Drug Chem Toxicol; 1984; 7(5):435-49. PubMed ID: 6510253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular and side effects of flesinoxan in conscious hypertensive dogs. Modulation by prazosin.
    Huber S; Grohs JG; Raberger G
    Eur J Pharmacol; 1991 Sep; 202(1):1-7. PubMed ID: 1786795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension.
    Frishman WH; Eisen G; Lapsker J
    Med Clin North Am; 1988 Mar; 72(2):441-8. PubMed ID: 2894488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy.
    Luther RR; Glassman HN; Sperzel WD; Steinberg FJ; Horton JK; Jordan DC
    J Hypertens Suppl; 1986 Dec; 4(5):S494-7. PubMed ID: 2883273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events.
    Somberg JC; Achari R; Laddu AR
    Am Heart J; 1991 Sep; 122(3 Pt 2):901-5. PubMed ID: 1678920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin.
    Jungers P; Ganeval D; Pertuiset N; Chauveau P
    Am J Med; 1986 May; 80(5B):94-9. PubMed ID: 2872815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
    Reid JL; Vincent J
    Cardiology; 1986; 73(3):164-74. PubMed ID: 2872958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment.
    Tomoda F; Takata M; Yoshida K; Yasumoto K; Mikawa M; Sasayama S
    Am J Hypertens; 1989 Nov; 2(11 Pt 1):834-9. PubMed ID: 2574044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Terazosin: a new antihypertensive agent with favorable effects on lipids.
    Luther RR
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):313-9. PubMed ID: 2570758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of beta 2-adrenoceptor-mediated mechanisms in the cardiovascular responses to alpha 1- and alpha 2-adrenoceptor antagonism in conscious, unrestrained, Long Evans and Brattleboro rats.
    Gardiner SM; Bennett T
    Br J Pharmacol; 1988 Jan; 93(1):9-22. PubMed ID: 2894880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cardiovascular effects of trimazosin.
    Constantine JW; Hess HJ
    Eur J Pharmacol; 1981 Sep; 74(2-3):227-38. PubMed ID: 6120084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure.
    Leier CV; Patterson SE; Huss P; Parrish D; Unverferth DV
    Am J Med Sci; 1986 Sep; 292(3):128-35. PubMed ID: 2875651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and pharmacodynamic studies with two alpha-adrenoceptor antagonists, doxazosin and prazosin in the rabbit.
    Hamilton CA; Reid JL; Vincent J
    Br J Pharmacol; 1985 Sep; 86(1):79-87. PubMed ID: 2864970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with essential hypertension.
    Lytle TB; Coles SJ; Waite MA
    J Clin Pharm Ther; 1991 Aug; 16(4):263-73. PubMed ID: 1682328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [3H]R-terazosin binds selectively to alpha1-adrenoceptors over alpha2-adrenoceptors - comparison with racemic [3H]terazosin and [3H]prazosin.
    Ireland LM; Cain JC; Rotert G; Thomas S; Shoghi S; Hancock AA; Kerwin JF
    Eur J Pharmacol; 1997 May; 327(1):79-86. PubMed ID: 9185839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship between terazosin dose and blood pressure response in hypertensive patients.
    Achari R; Hosmane B; Bonacci E; O'Dea R
    J Clin Pharmacol; 2000 Oct; 40(10):1166-72. PubMed ID: 11028256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-hypertension effect of vanylidilol: a phenylaldehyde alpha/beta-adrenoceptor blocker with endothelium-dependent and K+ channels opening-associated vasorelaxant activities.
    Chiu CC; Wu JR; Lee CH; Liou SF; Dai ZK; Chen IJ; Yeh JL
    Pharmacology; 2004 Mar; 70(3):140-51. PubMed ID: 14752234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.